Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 12/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.39 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2238684 | 0.86 | CHRM1 (0.36) | — | |
| Amenamevir SCHEMBL2238614 | 0.82 | HDAC1 (0.37) | — | |
| SCHEMBL14000159 | 0.82 | MAPT (0.37) | — | |
| SCHEMBL2238051 | 0.79 | HDAC1 (0.37) | — | |
| SCHEMBL21769567 | 0.76 | HDAC1 (0.38) | — | |
| SCHEMBL21769886 | 0.76 | POLB (0.36) | — | |
| SCHEMBL21769856 | 0.75 | L3MBTL1 (0.38) | — | |
| SCHEMBL2239362 | 0.74 | HDAC1 (0.38) | SLC6A9SLC6A5 | |
| SCHEMBL2242314 | 0.74 | ALDH1A1 (0.38) | — | |
| SCHEMBL2815306 | 0.74 | HTT (0.39) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465748-B2 | Antiherpesvirus drugs; great pharmacokinetics, good antivirus activity when administered orally at a low dose, high safety profile, less mutagenic concerns; N-(2,6-dimethylphenyl)-N-(2-{[4-(1,3-oxazol-4-yl)phenyl]amino)-2-oxoethyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| US-7465748-B2 | Antiherpesvirus drugs; great pharmacokinetics, good antivirus activity when administered orally at a low dose, high safety profile, less mutagenic concerns; N-(2,6-dimethylphenyl)-N-(2-{[4-(1,3-oxazol-4-yl)phenyl]amino)-2-oxoethyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |